Navigation Links
Tengion Provides Business Update and Reports Second Quarter 2013 Financial Results
Date:8/14/2013

, could place the Company's clinical trials on clinical hold; (ii) patients enrolled in the Neo-Urinary Conduit or Neo-Kidney Augment clinical trials may experience adverse events; (iii) the Company may have difficulty enrolling patients in its clinical trials; (iv) data from the Company's ongoing preclinical studies, including the GLP program for the Neo-Kidney Augment, may not continue to be supportive of advancing such preclinical product candidates; and (v) the Company may be unable to progress its product candidates that are undergoing preclinical testing into clinical trials and the Company may not be successful in designing such clinical trials in a manner that supports development of such product candidates. Any of these factors could delay one of the Company's clinical trials or cause the Company to terminate the development of one of its product candidates. For additional factors that could cause actual results to differ from expectations, you should refer to the reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release are made only as of the date hereof and the Company disclaims any intention or responsibility for updating predictions or expectations in this release.TENGION, INC.
(A Development-Stage Company)
Statements of Operations (in thousands, except per share data)(unaudited)Three Months EndedJune 30,Six Months EndedJune 30,2012201320122013Revenue$

—$

—$

—$

—Operating expenses:Research and development$

2,789$

2,480$

5,483$

4,660General and administrative1,4381,4452,8193,295Depreciation11562251145Other expense, net449192121 Total operating expenses4,3864,0788,6458,221 

Loss from operations(4,386)(4,078)(8,645)(8,221) 

Interest income42117Interest expense(151)(1,830)(325)(3,257)Change in fair value of embed
'/>"/>

SOURCE Tengion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Tengion Reports Second Quarter 2012 Financial Results
2. Tengion to Present at the BIO CEO & Investor Conference
3. Tengion Receives MPA Approval of CTA for Neo-Kidney Augment Phase 1 Trial in Sweden
4. MediPendant™ to Return to Television on May 20th New Television Campaign - Company Provides MediPendant™ Update
5. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
6. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
7. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
8. Elevate Provides Remote Access to Personal Health Records Using MyMedicalRecords.com
9. Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona
10. NexGen Biomedical, Inc. Provides New Insights Into Jett Travoltas Seizure Related Death
11. Concord Medical Announces its Successful Closing of the Acquisition of 52% Ownership in Changan Hospital and Provides Guidance for Financial Results of the Second Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... -- Reportlinker.com announces that a new market research ... Global Patient Scales Industry ... worldwide markets for Patient Scales in US$ Thousand ... & Baby Scales, Chair Scales, and Under Bed ... the US, Canada, Japan, Europe, Asia-Pacific, Latin America, ...
(Date:8/20/2014)... Phase I Trial of Plasma ... KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with a ... it has begun a Phase I, First in Human, ... the treatment of DME. The study,s Principal Investigator is ... Joslin Diabetes Center; Harvard Medical School Department of Ophthalmology, ...
(Date:8/19/2014)... , Aug. 19, 2014  Northwest Biotherapeutics (NASDAQ: ... developing DCVax® personalized immune therapies for solid tumor cancers, ... announced last Thursday, August 14, 2014, has closed.  The ... convertible at $7.30 per share of common stock.  The ... to purchase up to an additional 30% of these ...
Breaking Medicine Technology:Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3
(Date:8/20/2014)... 20, 2014 In its latest blog post, ... treatment program that gets clients off to a great start ... believe in, is highlighting an important and possibly life-changing – ... everyone who wants to understand the insidious nature of drug ... belief that drug abuse targets a certain socioeconomic group, such ...
(Date:8/20/2014)... Texas Medical Research Associates is looking for ... help test the effectiveness of a new drug looking to ... be eligible to participate in the study. , According to ... can lead to cardiovascular disease, the no. 1 cause of ... the risk of heart disease and stroke. People with high ...
(Date:8/20/2014)... sleep may wake up to worse consequences than nodding ... of being obese by age 21 was 20 percent ... of sleep a night, compared with their peers who ... Control and Prevention recommends nine to ten hours of ... of Public Health at Columbia University and the University ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 According to ... on August 7 in the multicounty litigation (MCL) case ... RE DEPUY ASR HIP IMPLANTS LITIGATION; no. BER-L-3971-11), nearly ... have been dismissed without prejudice. The cases enumerated in ... of being resolved.” The Rottenstein Law Group LLP, a ...
(Date:8/20/2014)... BCC Research ( http://www.bccresearch.com ) ... AND DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS , the ... to grow to $15.2 billion by 2019, with ... 15.9%. Increasing industrialization is driving significant growth ... expanding range of industrial applications such as military ...
Breaking Medicine News(10 mins):Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3Health News:Texas Medical Research Associates Announce New Study 2Health News:Teen sleeplessness piles on risk for obesity 2Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3
... The American Journal of Gastroenterology suggests that smoking may ... in those// who suffer from Crohn’s disease. Where the ... eventually require surgical treatment. ,“In patients who ... the small intestine, rather than the colon,” says study ...
... cold may cause uncommon ailments if neglected, specialists warn. // ... have always thought it is harmless. But specialists say it ... also negatively impact vision or cause harm to any part ... cases of chronic sinusitis because of unchecked pollution. Chronic sinus ...
... has been recommended for medical conditions such as endometriosis, ... choice for women who dislike menstruation or find it ... and is it a reasonable lifestyle choice, asks Paula ... ,Birth control options that reduce or eliminate periods ...
... new cancer research study that may be the ‘last best ... to discover the genetic and environmental factors that cause and ... aims to enroll a geographically and ethnically diverse group of ... pave the way for the next generation of American Cancer ...
... the counter (OTC) drugs can be highly addictive, warn two ... of dependency on OTC drugs is often forgotten, write Drs ... months, they describe seeing three patients with addictions to Nurofen ... started using the product for its approved indications, but their ...
... benefit from having a tonsillectomy in the short term, ... and any benefits have to be balanced against the ... small study of adults from Finland showed that tonsillectomy ... days, compared with watchful waiting. ,But despite ...
Cached Medicine News:Health News:A Cold Shoulder to Cold - At Your Risk 2Health News:Should Menstrual Suppression Be a Lifestyle Choice? 2Health News:American Cancer Society Launches Major New Study 2Health News:American Cancer Society Launches Major New Study 3Health News:Is It Worth Having Surgery to Remove Your Tonsils? 2
... contamination, which causes false ... Hydrophobic, nonwicking and self-sealing ... pass through these aerosol-resistant ... to tips with absorption ...
Inquire...
... Finntip Filters are ideal ... methods, or for any work ... They are designed for pipetting ... samples, and other. For applications ...
... Finntip Filters are ideal for ... or for any work where ... are designed for pipetting DNA/RNA ... and other. For applications requiring ...
Medicine Products: